조현병 환자에서 항정신약물이 대사지표에 미치는 영향 조사 - 1년 추적연구 = A Study on Changes of Metabolic Parameters with Antipsychotic Treatment in Schizophrenic Patients : 1 Year Prospective Natualistic Study

다국어 초록 (Multilingual Abstract)

Objectives : Schizophrenia patients are known to be more prone to metabolic disease than normal people. This study aimed to identifythe changes in metabolic parameters of schizophrenia patients using atypical antipsychotic drugs for 1 year.
Methods : A total of 200 schizophrenia patients were recruited and categorized into the aripiprazole-treatment group and controlgroup taking 5 atypical antipsychotic drugs. Comparative analysis were between groups. The prescriptions of psychotropic drugswere collected by a review of medical records. Blood was collected after fasting for 12 hours at the starting point of treatment andthe 12th month, and patient medical records were evaluated for basici nformation and treatment history. Physical measurement,the prevalence of metabolic syndrome and metabolic parameters were studied using ATP-III diagnostic criteria.
Results : From the study, the aripiprazole-treatment group had a mean weight increase of 0.6 kg and the control group had amean weight increase of 6.5 kg at the 1 year follow-up, showing a significant difference between the two groups. There were alsosignificant differences between the two groups in waist size, systolic and diastolic blood pressure, fasting blood sugar, total cholesterol,triglyceride, HDL-choleseterol and prolactin level. Along with meaningful improvement of the symptoms, aripiprazoletreatmentgroup showed less effect on in abdominal obesity, diabetes, blood pressure, cholesterol and prolactin than other atypicalantipsychotic drugs.
Conclusion : Therapeutic intervention such as diagnosis, treatment, weight management and diet improvement is necessary forschizophrenia patients. Psychiatric symptoms as well as internal meicine-related problems such as metabolic disease need to beaddressed in case management.

참고문헌 (Reference)

1 Meyer JM, "The effects of antipsychotic therapy on serum lipids: a comprehensive review" 70 : 1-17, 2004

2 Meyer JM, "The effects of antipsychotic therapy on serum lipids : a comprehensive review" 70 : 1-17, 2004

3 Hanssens L, "The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients:results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)" 8 : 95-, 2008

4 American Psychiatric Association, "The diagnostic and statistical manual of mental disorder" American Psychiatric Press 1994

5 "The asia-pacific perspective: redefining obesity and its treatment" Health Communications Australia Pty Limit 2000

6 고유경, "The Prevalence of Metabolic Syndrome in Schizophrenic Patients Using Antipsychotics" 대한정신약물학회 11 (11): 80-88, 2013

7 Takahata K, "Striatal and extrastriatal dopamine D2 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [11C]raclopride and [11C]FLB457" 222 : 165-172, 012

8 McEvoy JP, "Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trialsof Intervention Effectiveness(CATIE) schizophrenia trial and comparison with national estimates from NHANES III" 80 : 19-32, 2005

9 Marder SR, "Physical health monitoring of patients with schizophrenia" 161 : 1334-1349, 2004

10 Casey DE, "Metabolic issues and cardiovascular disease in patients with psychiatric disorders" 118 : 15-22, 2005

11 Lambert M, "Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence" 19 : 415-422, 2004

12 Lambert M, "Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence" 19 : 415-422, 2004

13 "Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adult (Adult Treatment Panel III)" 285 : 2486-2497, 2001

14 Haupt DW, "Different metabolic effects of antipsychotic treatments" 16 : 149-155, 2006

15 L'Italien GJ, "Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo" 68 : 1510-1516, 2007

16 Byerly M, "Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives" 27 : 639-661, 2007

17 Baptista T, "Body weight gain induced by antipsychotic drugs; mechanisms and management" 100 : 3-16, 1999

18 Faulkner G, "Body mass index, waist circumference and quality of life in individuals with schizophrenia" 90 : 174-178, 2007

19 Saravane D, "Avec le soutien institutionnel du laboratoire Lilly. Drawing up guidelines for the attendance of physical health of patients with severe mental illness" 35 : 330-339, 2009

20 Allison DB, "Antipsychotic-induced weight gain: a review of the literature" 62 : 22-31, 2001

21 Czobor P, "Antipsychotic-induced weight gain and therapeutic response: a differential association" 22 : 244-251, 2002

22 Compton MT, "Antipsychotic-induced hyperprolactinemia and sexual dysfunction" 36 : 143-164, 2002

23 Ma GF, "Agonist and antagonist effects of aripiprazole on D2-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone" 18 : 1-9, 2014

24 Newcomer JW, "Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia" 59 : 337-345, 2002

25 Fleischhacker WW, "A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia" 65 : 510-517, 2009

26 McQuade RD, "A comprehensive of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study" 65 (65): 47-56, 2004